Minor Cannabinoids: Commercial Promises vs. Scientific Evidence

Minor cannabinoids like CBG, CBN, CBC, THCV, and CBDV are increasingly marketed in oils, gummies, and supplements with claims ranging from improved sleep to appetite control. However, a guide from Rare Cannabinoid Company highlights a significant gap between commercial marketing claims and actual human clinical evidence. While these compounds show promise in preclinical studies, rigorous human trials remain limited for most applications. Consumers in Puerto Rico should approach these products with caution and consult healthcare providers before use. As the market expands, regulatory oversight and evidence-based research become increasingly important for patient safety.